{
  "catalogId": "277b4c2f-7788-4ec0-bd09-252bc74abb95",
  "name": "OPDIVO",
  "status": "draft",
  "category": "prescription",
  "registrationValidity": "valid",
  "registrationNumber": "153 55 34333 00",
  "treatmentDescriptions": "Unresectable or Metastatic Melanoma:Opdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and pediatric patients 12 years and older.Adjuvant Treatment of Melanoma:OPDIVO is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, IIC, III, or IV melanoma.Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer:OPDIVO, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors &#8805;4 cm or node positive) non-small cell lung cancer (NSCLC).Neoadjuvant and Adjuvant Treatment of Resectable Non-Small Cell Lung Cancer:OPDIVO, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors &#8805;4 cm or node positive) NSCLC with tumour cell PD-L1 expression &#8805; 1% and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by single-agent OPDIVO as adjuvant treatment after surgery.Metastatic Non-Small Cell Lung Cancer:- Opdivo, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.- Opdivo is indicated for the treatment of adult patients with metastatic non small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.Renal Cell Carcinoma:- Opdivo as a single agent is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) in patients who have received prior anti-angiogenic therapy.- Opdivo in combination with ipilimumab is indicated for the first line treatment of adult patients with intermediate or poor risk, advanced renal cell carcinoma (RCC).- OPDIVO, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC.Classical Hodgkin Lymphoma:Opdivo is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after:- autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or- 3 or more lines of systemic therapy that includes autologous HSCT.Squamous Cell Carcinoma of the Head and Neck:Opdivo is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer- OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).- OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.Urothelial carcinoma:- OPDIVO is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC.- OPDIVO, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.- Opdivo is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who:     * have disease progression during or following platinum-containing chemotherapy     * have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.Hepatocellular Carcinoma:Opdivo, in combination with ipilimumab, is indicated for the treatment of adult patients with hepatocellular carcinoma (HCC) Child-Pugh A who have been previously treated with sorafenib.Esophageal cancer:- OPDIVO is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT). - OPDIVO is indicated for the treatment of adult patients with unresectable, advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy.- OPDIVO in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma with tumour cell PD-L1 expression &#8805; 1%.- OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma with tumour cell PD-L1 expression &#8805; 1%.Malignant Pleural Mesothelioma:OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma:OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.",
  "termsOfIssue": "Prescription required",
  "form": "concentrate for solution for infusion",
  "route": "i.v",
  "site": "",
  "method": "",
  "administrationNotes": "",
  "ingredients": "NIVOLUMAB/ML",
  "codes": {
    "atc5": {
      "system": "WHO ATC Classification",
      "code": "L01XC17",
      "name": "NIVOLUMAB"
    }
  },
  "contraindications": "",
  "sideEffect": "",
  "warnings": "תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת",
  "alternativeMedications": [],
  "packaging": [
    {
      "name": "OPDIVO 10MG/ML VIAL 4ML",
      "manufacturer": {
        "name": "ב.מ.ס",
        "countryOfOrigin": "IL"
      },
      "strength": [
        {
          "value": 4.0,
          "unit": "ml"
        }
      ],
      "quantity": {
        "value": 4.0,
        "unit": "units"
      },
      "packagingDescription": "VIAL GLASS TYPE I",
      "shelfLife": "36",
      "storageConditions": "",
      "codes": {
        "moh": "7623",
        "yarpa": "82231",
        "pharmasoft": "15445",
        "barcode": "7290014396111"
      },
      "manufacturersAdministrationRecommendation": "",
      "pricing": {
        "currency": "ILS",
        "maxWholesalePrice": 1703.835372,
        "retailMargin": 17.5,
        "maxRetailPrice": 2002.006563,
        "maxPriceWithVAT": 2362.367639
      },
      "formulation": ""
    }
  ],
  "metadata": {
    "version": "1.5",
    "lastUpdated": "2025-08-01T18:03:52.014655",
    "tags": [
      "needs_manual_review"
    ],
    "availableApiOptions": [
      {
        "name": "OPDIVO",
        "registration": "153 55 34333 00",
        "form": ""
      }
    ],
    "smartValidation": {
      "extractedFrom": "OPDIVO 10MG/ML VIAL 4ML",
      "processedBy": "smart_validation",
      "bestMatchScore": 0.010000000000000002,
      "status": "failed_match"
    }
  }
}